Evidence map›Paper›PMID 27435725›Full record

ArticleRespiratory research2016

Pulmonary effects of inhalation of spark-generated silver nanoparticles in Brown-Norway and Sprague-Dawley rats.

Joanna Seiffert, Alison Buckley, Bey Leo, Nicholas G Martin, Jie Zhu, Ranran Dai, Farhana Hussain, Chang Guo, James Warren, Alan Hodgson and 8 more

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Joanna SeiffertAirways Disease, National Heart & Lung Institute, Imperial College London, Dovehouse St, London, SW3 6LY, UK.
Alison BuckleyNanoparticle Inhalation Research Group, Public Health England, Oxfordshire, UK.
Bey LeoDepartment of Material Science, Chemistry and the London Centre for Nanotechnology, Imperial College, London, SW3, UK.
Nicholas G MartinDepartment of Clinical Biochemistry, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, W6 8RF, UK.
Jie ZhuAirways Disease, National Heart & Lung Institute, Imperial College London, Dovehouse St, London, SW3 6LY, UK.
Ranran DaiAirways Disease, National Heart & Lung Institute, Imperial College London, Dovehouse St, London, SW3 6LY, UK.
Farhana HussainAirways Disease, National Heart & Lung Institute, Imperial College London, Dovehouse St, London, SW3 6LY, UK.
Chang GuoNanoparticle Inhalation Research Group, Public Health England, Oxfordshire, UK.
James WarrenNanoparticle Inhalation Research Group, Public Health England, Oxfordshire, UK.
Alan HodgsonNanoparticle Inhalation Research Group, Public Health England, Oxfordshire, UK.
Jicheng GongNicholas School of Environment & Duke Global Health Institute, Duke University, Durham, USA.
Mary P RyanDepartment of Material Science, Chemistry and the London Centre for Nanotechnology, Imperial College, London, SW3, UK.
Junfeng Jim ZhangNicholas School of Environment & Duke Global Health Institute, Duke University, Durham, USA.
Alexandra PorterDepartment of Material Science, Chemistry and the London Centre for Nanotechnology, Imperial College, London, SW3, UK.
Terry D TetleyAirways Disease, National Heart & Lung Institute, Imperial College London, Dovehouse St, London, SW3 6LY, UK.
Andrew GowDepartment of Pharmacology and Toxicology, Rutgers University, Piscataway, NJ, USA.
Rachel SmithNanoparticle Inhalation Research Group, Public Health England, Oxfordshire, UK.
Kian Fan ChungAirways Disease, National Heart & Lung Institute, Imperial College London, Dovehouse St, London, SW3 6LY, UK. f.chung@imperial.ac.uk.ORCID 0000-0001-7101-1426
Imperial College London · GBPublic Health England · GBLondon Centre for Nanotechnology · GBDuke University · USImperial College Healthcare NHS Trust · GBLung Institute · USRutgers, The State University of New Jersey · US

Funding

Scientific CoreU19ES019536 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TETLEY, TERESA DOROTHY, ZHANG, JUNFENG · 2010 to 2014
$4.6M
NIEHS NIH HHS U19 ES019536
6 · The paper itself

Abstract

backgroundThe increasing use of silver nanoparticles (AgNPs) in consumer products is concerning. We examined the potential toxic effects when inhaled in Brown-Norway (BN) rats with a pre-inflammatory state compared to Sprague-Dawley (SD) rats.

methodsWe determined the effect of AgNPs generated from a spark generator (mass concentration: 600-800 μg/mm(3); mean diameter: 13-16 nm; total lung doses: 8 [Low] and 26-28 [High] μg) inhaled by the nasal route in both rat strains. Rats were sacrificed at day 1 and day 7 after exposure and measurement of lung function.

resultsIn both strains, there was an increase in neutrophils in bronchoalveolar lavage (BAL) fluid at 24 h at the high dose, with concomitant eosinophilia in BN rats. While BAL inflammatory cells were mostly normalised by Day 7, lung inflammation scores remained increased although not the tissue eosinophil scores. Total protein levels were elevated at both lung doses in both strains. There was an increase in BAL IL-1β, KC, IL-17, CCL2 and CCL3 levels in both strains at Day 1, mostly at high dose. Phospholipid levels were increased at the high dose in SD rats at Day 1 and 7, while in BN rats, this was only seen at Day 1; surfactant protein D levels decreased at day 7 at the high dose in SD rats, but was increased at Day 1 at the low dose in BN rats. There was a transient increase in central airway resistance and in tissue elastance in BN rats at Day 1 but not in SD rats. Positive silver-staining was seen particularly in lung tissue macrophages in a dose and time-dependent response in both strains, maximal by day 7. Lung silver levels were relatively higher in BN rat and present at day 7 in both strains.

conclusionsPresence of cellular inflammation and increasing silver-positive macrophages in lungs at day 7, associated with significant levels of lung silver indicate that lung toxicity is persistent even with the absence of airway luminal inflammation at that time-point. The higher levels and persistence of lung silver in BN rats may be due to the pre-existing inflammatory state of the lungs.

Indexed as

AnimalsBronchoalveolar Lavage FluidCytokinesDose-Response Relationship, DrugInflammation MediatorsInhalation ExposureLungMacrophages, AlveolarMaleMetal NanoparticlesPhospholipidsPneumoniaPulmonary EosinophiliaPulmonary Surfactant-Associated Protein DRats, Inbred BNRats, Sprague-DawleyCytokinesInflammation MediatorsPhospholipidsPulmonary Surfactant-Associated Protein DSilverInflammationInhalationLungsSilver nanospheres

Identifiers

PMID27435725
PMCPMC4950697
OpenAlexW2494597898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.